TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04138654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed meat product
Description: 300 grams per day during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed meat product
Description: 300 grams per day during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White meat wash-out
Description: 300 grams per day during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White meat wash-out
Description: 300 grams per day during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed meat products enriched with natural compounds
Description: 300 grams per day during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed meat products enriched with natural compounds
Description: 300 grams per day during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds
Description: 3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds
Description: 3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
Study: NCT02384889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine
Description: Active Therapy with DFMO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparitor
Study: NCT04022226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Induction agent that does not suppress infra-slow waves
Study: NCT02694510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light-protection of TPN solutions
Description: TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light-protection of TPN solutions
Description: TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
Study: NCT01753856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Administered SC
Study: NCT00634725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03716778

Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric rehabilitation sessions
Description: ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric rehabilitation sessions
Description: ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode.
Study: NCT01753856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Demeclocycline
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demeclocycline
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Supplement
Description: Administered orally
Study: NCT01609712

Intervention type: PROCEDURE
Intervention: Radiofrequency Kyphoplasty
Description: Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved.
Study: NCT04274231

Intervention type: GENETIC
Intervention: different effection
Description: Analysis of the reasons for treatment
Study: NCT00699387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
Study: NCT01604577

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interactive educational intervention
Description: Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
Study: NCT01105975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks
Study: NCT01753856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Description: Administered orally
Study: NCT02806336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi Modal Balance Training
Description: Group balance class, obstacle course, strengthening exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi Modal Balance Training
Description: Group balance class, obstacle course, strengthening exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Nutritional counseling to achieve 500 kcal standard hypocaloric diet
Study: NCT00152477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP791 10mg/kg
Description: CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP791 10mg/kg
Description: CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP791 20mg/kg
Description: CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP791 20mg/kg
Description: CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
Study: NCT01420692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir
Description: Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
Study: NCT02876458

Intervention type: OTHER
Group type: OTHER
Intervention: Immediate coronary angiogram
Description: An immediate coronary angiogram will be performed

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed coronary angiogram
Description: A delayed coronary angiogram (between 48 to 96 hours) will be performed
Study: NCT02160665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.05%
Description: Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of Test product (G \& W Laboratories, Inc.)

Intervention type: DRUG
Group type: OTHER
Intervention: Reference: Tazorac Cream, 0.05%
Description: Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
Study: NCT03471338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Description: At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard Psychological care
Description: At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit.
Study: NCT00434447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT00610350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: 24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
Study: NCT04405778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-102
Description: TAK-102 intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-102
Description: TAK-102 intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-102
Description: TAK-102 intravenous infusion
Study: NCT00441142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
Study: NCT01105975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LY2484595
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Statins
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Statins
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Statins
Description: Administered daily by mouth for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Statins
Description: Administered daily by mouth for 12 weeks
Study: NCT02824198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine (5 dose formulation)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, NaCl 0.9%
Description: 0.5 mL, Subcutaneous
Study: NCT00018096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS endotoxin, saline, HDM
Description: instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
Study: NCT01144559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus Administered
Description: Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
Study: NCT03516370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharomyces Boulardii 250 MG
Description: all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG
Description: all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Study: NCT01223274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP/PEEP
Description: Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard management practices
Description: Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
Study: NCT03676569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADRC transplantation in autoimmune refractory epilepsy
Study: NCT04195919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Participants receive Single oral administration of Evogliptin 5mg on day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period
Study: NCT01331499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar Sealer (Aquamantys)
Description: Standard of care blood sparing techniques along with the use of bipolar sealer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care blood sparing techniques without the useof bipolar sealer
Study: NCT02994407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months.